5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The recent development of assays that accurately quantify neurofilament light, a neuronal cytoskeleton protein, in plasma has generated a vast literature supporting that it is a sensitive, dynamic, and robust biomarker of neuroaxonal damage. As a result, efforts are now made to introduce plasma neurofilament light into clinical routine practice, making it an easily accessible complement to its cerebrospinal fluid counterpart. An increasing literature supports the use of plasma neurofilament light in differentiating neurodegenerative diseases from their non-neurodegenerative mimics and suggests it is a valuable biomarker for the evaluation of the effect of putative disease-modifying treatments (e.g. in multiple sclerosis). More contexts of use will likely emerge over the coming years. However, to assist clinical interpretation of laboratory test values, it is crucial to establish normal reference intervals. In this study, we sought to derive reliable cut-offs by pooling quantified plasma neurofilament light in neurologically healthy participants (5–90 years) from eight cohorts. A strong relationship between age and plasma neurofilament light prompted us to define the following age-partitioned reference limits (upper 95 th percentile in each age category): 5–17 years = 7 pg/mL; 18–50 years = 10 pg/mL; 51–60 years = 15 pg/mL; 61–70 years = 20 pg/mL; 70 + years = 35 pg/mL. The established reference limits across the lifespan will aid the introduction of plasma neurofilament light into clinical routine, and thereby contribute to diagnostics and disease-monitoring in neurological practice.

          Abstract

          Simrén et al. report age-stratified cut-offs for plasma neurofilament light, based on a large material of healthy individuals across the ages 5–90 years. The findings will assist clinical implementation of plasma neurofilament light in clinical routine, by simplifying interpretation of concentrations across the lifespan as neurofilament light increases with age.

          Graphical Abstract

          Graphical abstract

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: found

          Neurofilaments as biomarkers in neurological disorders

          Neuroaxonal damage is the pathological substrate of permanent disability in various neurological disorders. Reliable quantification and longitudinal follow-up of such damage are important for assessing disease activity, monitoring treatment responses, facilitating treatment development and determining prognosis. The neurofilament proteins have promise in this context because their levels rise upon neuroaxonal damage not only in the cerebrospinal fluid (CSF) but also in blood, and they indicate neuroaxonal injury independent of causal pathways. First-generation (immunoblot) and second-generation (enzyme-linked immunosorbent assay) neurofilament assays had limited sensitivity. Third-generation (electrochemiluminescence) and particularly fourth-generation (single-molecule array) assays enable the reliable measurement of neurofilaments throughout the range of concentrations found in blood samples. This technological advancement has paved the way to investigate neurofilaments in a range of neurological disorders. Here, we review what is known about the structure and function of neurofilaments, discuss analytical aspects and knowledge of age-dependent normal ranges of neurofilaments and provide a comprehensive overview of studies on neurofilament light chain as a marker of axonal injury in different neurological disorders, including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis and Parkinson disease. We also consider work needed to explore the value of this axonal damage marker in managing neurological diseases in daily practice.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

            The detection of single protein molecules1,2 in blood could help identify many new diagnostic protein markers. We report an approach for detecting hundreds to thousands of individual protein molecules simultaneously that enables the detection of very low concentrations of proteins. Proteins are captured on microscopic beads and labeled with an enzyme, such that each bead has either one or zero enzyme-labeled proteins. By isolating these beads in arrays of 50-femtoliter reaction chambers, single proteins can be detected by fluorescence imaging. By singulating molecules in these arrays, ~10–20 enzymes can be detected in 100 μL (~10−19 M). Single molecule enzyme-linked immunosorbent assays (digital ELISA) based on singulation of enzyme labels enabled the detection of clinically-relevant proteins in serum at concentrations (<10−15 M) much lower than conventional ELISA3-5. Digital ELISA detected prostate specific antigen in all tested sera from patients who had undergone radical prostatectomy, down to 14 fg/mL (0.4 fM).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology : A Systematic Review and Meta-analysis

              How do levels of neurofilament light in cerebrospinal fluid (cNfL) compare between neurological conditions and with healthy controls? Among 10 059 individuals in this systematic review and meta-analysis, cNfL was elevated in most neurological conditions compared with healthy controls, and the magnitude of the increase varies extensively. Although cNfL overlaps between most clinically similar conditions, its distribution did not overlap in frontotemporal dementia and other dementias or in Parkinson disease and atypical parkinsonian syndromes. The cNfL is a marker of neuronal damage and may be useful to differentiate some clinically similar conditions, such as frontotemporal dementia from Alzheimer disease and Parkinson disease from atypical parkinsonian syndromes. This systematic review and meta-analysis assesses the associations of age, sex, and diagnosis with neurofilament light in cerebrospinal fluid and evaluates its potential in discriminating clinically similar conditions. Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date. To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions. PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid ) in neurological or psychiatric conditions and/or in HC. Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex. Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept. The cNfL levels adjusted for age and sex across diagnoses. Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes. These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.
                Bookmark

                Author and article information

                Contributors
                Journal
                Brain Commun
                Brain Commun
                braincomms
                Brain Communications
                Oxford University Press
                2632-1297
                2022
                04 July 2022
                04 July 2022
                : 4
                : 4
                : fcac174
                Affiliations
                Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41345 Gothenburg, Sweden
                Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 43180 Gothenburg, Sweden
                Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41345 Gothenburg, Sweden
                Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 43180 Gothenburg, Sweden
                Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41345 Gothenburg, Sweden
                Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 43180 Gothenburg, Sweden
                Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation , 08005 Barcelona, Spain
                IMIM (Hospital del Mar Medical Research Institute) , 08003 Barcelona, Spain
                Servei de Neurologia, Hospital del Mar , 08003 Barcelona, Spain
                Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) , 08003 Madrid, Spain
                Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia , 25125 Brescia, Italy
                Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, University of Gothenburg , 41119 Gothenburg, Sweden
                Department of Integrative Medical Biology, Umeå University , 90736 Umeå, Sweden
                Umeå Center for Functional Brain Imaging (UFBI), Umeå University , 90736 Umeå, Sweden
                Department of Radiation Sciences, Umeå University , 90185 Umeå, Sweden
                Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli , 25125 Brescia, Italy
                Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, University of Gothenburg , 41119 Gothenburg, Sweden
                Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, University of Gothenburg , 41119 Gothenburg, Sweden
                Department of Gynecology, Ghent University Hospital , B-9820 Ghent, Belgium
                Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41345 Gothenburg, Sweden
                The Institute of Stress Medicine, Region of Västra Götaland , 41319 Gothenburg, Sweden
                The Institute of Stress Medicine, Region of Västra Götaland , 41319 Gothenburg, Sweden
                School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , 41319 Gothenburg, Sweden
                Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41345 Gothenburg, Sweden
                Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 43180 Gothenburg, Sweden
                Department of Neurodegenerative Disease, Institute of Neurology, University College London , WC1E 6BT London, UK
                UK Dementia Research Institute, University College London , WC1E 6BT London, UK
                Hong Kong Center for Neurodegenerative Diseases , Hong Kong, China
                Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41345 Gothenburg, Sweden
                Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 43180 Gothenburg, Sweden
                Author notes
                Correspondence to: Joel Simrén, MD Institute of Neuroscience and Physiology Department of Psychiatry and Neurochemistry The Sahlgrenska Academy, University of Gothenburg SE 43180 Gothenburg, Sweden E-mail: joel.simren@ 123456gu.se
                Author information
                https://orcid.org/0000-0001-5081-6604
                https://orcid.org/0000-0001-6193-6193
                https://orcid.org/0000-0001-9340-9814
                https://orcid.org/0000-0001-6738-6495
                https://orcid.org/0000-0003-3930-4354
                Article
                fcac174
                10.1093/braincomms/fcac174
                9297091
                35865350
                d5d93525-fb76-4d87-aa75-a332da696b0c
                © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 15 February 2022
                : 05 May 2022
                : 30 June 2022
                Page count
                Pages: 8
                Funding
                Funded by: Stiftelsen för GamLa Tjänarinnor, doi 10.13039/100010815;
                Funded by: Swedish Research Council, doi 10.13039/501100004359;
                Funded by: European Research Council, doi 10.13039/501100000781;
                Funded by: Alzheimer Drug Discovery Foundation, doi 10.13039/100002565;
                Funded by: Alzheimer's Association, doi 10.13039/100000957;
                Funded by: Erling-Persson Family Foundation, doi 10.13039/100007436;
                Funded by: National Institutes of Health, doi 10.13039/100000002;
                Funded by: Alzheimerfonden, doi 10.13039/501100008599;
                Funded by: Instituto de Salud Carlos III, doi 10.13039/501100004587;
                Funded by: Ministry of Health, doi 10.13039/100009647;
                Categories
                Original Article
                AcademicSubjects/MED00310
                AcademicSubjects/SCI01870
                Editor's Choice

                neurofilament light,plasma,biomarkers,reference limits,clinical chemistry

                Comments

                Comment on this article